OptimizeRx (NASDAQ:OPRX) Upgraded to “Strong-Buy” at Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday.

A number of other analysts also recently commented on the stock. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Lake Street Capital decreased their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. B. Riley Financial dropped their price target on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings downgraded OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Finally, UBS Group set a $10.00 price objective on OptimizeRx in a research note on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.43.

OptimizeRx Price Performance

OptimizeRx stock traded up $0.13 during midday trading on Friday, hitting $6.41. The company’s stock had a trading volume of 166,535 shares, compared to its average volume of 465,243. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16. The stock’s 50-day moving average price is $5.45 and its 200-day moving average price is $7.76. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $22.25. The company has a market capitalization of $120.25 million, a PE ratio of 18.31 and a beta of 1.08.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. The company had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.74 million. Analysts anticipate that OptimizeRx will post 0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Segall Bryant & Hamill LLC purchased a new position in shares of OptimizeRx in the first quarter worth approximately $1,185,000. Quantinno Capital Management LP lifted its position in shares of OptimizeRx by 180.1% in the 1st quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after acquiring an additional 31,518 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in OptimizeRx by 1.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after purchasing an additional 11,247 shares during the period. Renaissance Technologies LLC boosted its stake in OptimizeRx by 633.2% in the 1st quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after purchasing an additional 187,278 shares during the period. Finally, Sei Investments Co. grew its position in OptimizeRx by 83.4% during the 1st quarter. Sei Investments Co. now owns 98,633 shares of the company’s stock worth $619,000 after purchasing an additional 44,844 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.